Maroto, P, Porta, C, Capdevila, J, Apolo, AB, Viteri, S, Rodriguez-Antona, C, Martin, L, Castellano, D. Cabozantinib for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology. 2022; 14DOI:10.1177/17588359221107112. PMID:35847482. IF:4.900(Q2/4D).

Castellano, D, Apolo, AB, Porta, C, Capdevila, J, Viteri, S, Rodriguez-Antona, C, Martin, L, Maroto, P. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology. 2022; 14DOI:10.1177/17588359221108691. PMID:35923927. IF:4.900(Q2/4D).

Parra-Perez, AM, Perez-Jimenez, A, Gris-Cardenas, I, Bonel-Perez, GC, Carrasco-Diaz, LM, Mokhtari, K, Garcia-Salguero, L, Lupianez, JA, Rufino-Palomares, EE. Involvement of the PI3K/AKT Intracellular Signaling Pathway in the AntiCancer Activity of Hydroxytyrosol, a Polyphenol from Olea europaea, in Hematological Cells and Implication of HSP60 Levels in Its Anti-Inflammatory Activity. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(13)DOI:10.3390/ijms23137053. PMID:35806065. IF:5.600(Q1/3D).

Alvarez-Larran, A, Garrote, M, Ferrer-Marin, F, Perez-Encinas, M, Mata-Vazquez, MI, Bellosillo, B, Arellano-Rodrigo, E, Gomez, M, Garcia, R, Garcia-Gutierrez, V, Gasior, M, Cuevas, B, Angona, A, Gomez-Casares, MT, Martinez, CM, Magro, E, Ayala, R, del Orbe-Barreto, R, Perez-Lopez, R, Fox, ML, Raya, JM, Guerrero, L, Garcia-Hernandez, C, Caballero, G, Murillo, I, Xicoy, B, Ramirez, MJ, Carreno-Tarragona, G, Hernandez-Boluda, JC, Pereira, A. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. CANCER. 2022; 128(13)DOI:10.1002/cncr.34195. PMID:35417564. IF:6.200(Q1/3D).